SANUWAVE Health Terminates Material Agreement
Ticker: SNWV · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1417663
| Field | Detail |
|---|---|
| Company | Sanuwave Health, Inc. (SNWV) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, financial-statements, regulation-fd
TL;DR
SANUWAVE terminated a big deal, filing an 8-K with financials.
AI Summary
SANUWAVE Health, Inc. announced on June 25, 2024, the termination of a material definitive agreement. The company is also providing a Regulation FD disclosure and filing financial statements and exhibits as part of this 8-K report.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material agreement introduces uncertainty regarding the company's business relationships and financial outlook.
Key Players & Entities
- SANUWAVE Health, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- June 25, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement was terminated by SANUWAVE Health, Inc.?
The filing does not specify the exact nature of the material definitive agreement that was terminated.
What is the significance of the Regulation FD disclosure in this filing?
A Regulation FD disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 25, 2024.
What is SANUWAVE Health, Inc.'s principal executive office address?
The principal executive offices are located at 11495 Valley View Road, Eden Prairie, Minnesota 55344.
What is SANUWAVE Health, Inc.'s IRS Employer Identification Number?
SANUWAVE Health, Inc.'s IRS Employer Identification Number is 20-1176000.
Filing Stats: 631 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-06-26 07:22:03
Filing Documents
- ef20031723_8k.htm (8-K) — 32KB
- ef20031723_ex99-1.htm (EX-99.1) — 8KB
- image00001.jpg (GRAPHIC) — 6KB
- 0001140361-24-031382.txt ( ) — 173KB
- snwv-20240625.xsd (EX-101.SCH) — 4KB
- snwv-20240625_lab.xml (EX-101.LAB) — 20KB
- snwv-20240625_pre.xml (EX-101.PRE) — 14KB
- ef20031723_8k_htm.xml (XML) — 4KB
02
Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on August 23, 2023, Sanuwave Health, Inc., a Nevada corporation ("the Company"), SEP Acquisition Corp., a Delaware corporation ("SEPA"), and SEP Acquisition Holdings Inc., a Delaware corporation and a wholly-owned subsidiary of SEPA ("Merger Sub"), entered into that certain Agreement and Plan of Merger (as amended from time to time, the "Merger Agreement"), pursuant to which Merger Sub would merge with and into the Company with the Company continuing as the surviving entity and wholly-owned subsidiary of SEPA. On June 25, 2024, the Company delivered a notice to SEPA terminating the Merger Agreement . The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which was previously filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on August 23, 2023 and is incorporated herein by reference.
01
Item 7.01 Regulation FD Disclosure. On June 26, 2024, the Company issued a press release announcing its termination of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Consequently, it is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. Such materials may only be incorporated by reference into another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated June 26, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANUWAVE HEALTH, INC. Dated: June 26, 2024 By: /s/ Peter Sorensen Name: Peter Sorensen Title: Chief Financial Officer